Breaking News Instant updates and real-time market news.

KNSA

Kiniksa

$26.47

1.62 (6.52%)

09:04
09/15/18
09/15
09:04
09/15/18
09:04

Kiniksa presents Phase 1a/1b data for KPL-716 in atopic dermatitis

Kiniksa Pharmaceuticals presented Phase 1a/1b clinical data for KPL-716, an investigational fully-human monoclonal antibody that targets oncostatin M receptor beta, at the 27th European Academy of Dermatology and Venereology Congress. In this First-in-Human clinical trial, single intravenous and subcutaneous doses of KPL-716 were well-tolerated in both adult healthy volunteers and adult subjects with moderate-to-severe atopic dermatitis experiencing moderate-to-severe pruritus, the company said. KPL-716 also demonstrated a reduction in pruritus, it added. "The results support Kiniksa's plans for expanding clinical development into multiple chronic pruritic diseases, including prurigo nodularis," said the company. In total, 50 healthy volunteers and 32 subjects with moderate-to-severe atopic dermatitis experiencing moderate-to-severe pruritus received a single dose of KPL-716 or placebo in the Phase 1a/1b clinical trial, with the top dose of 20 mg/kg IV in healthy volunteers and 7.5 mg/kg IV in subjects with atopic dermatitis. The mean percentage change in weekly-average Worst-Itch Numeric Rating Scale decreased by 40.4% in KPL-716 recipients compared to a 17.6% decrease in placebo recipients at Day 28 in the absence of concomitant TCS. The mean percentage change in Pruritus Visual Analog Scale decreased by 55.4% in KPL-716 recipients compared to a 10.4% decrease in placebo recipients at Day 28 in the absence of concomitant TCS. "The KPL-716 Phase 1a/1b results met a high hurdle for success, as the placebo-controlled, single-dose safety and pharmacokinetics study also demonstrated reduction in pruritus," said John F. Paolini, MD, PhD, Chief Medical Officer of Kiniksa. "We are now considering advancement of KPL-716 into multiple chronic pruritic diseases, including prurigo nodularis. Additionally, the observed reduction in EASI scores after only a single dose of KPL-716 is encouraging. Our ongoing repeat-single-dose trial in atopic dermatitis subjects will provide longer-term exposures and data on these inflammatory disease response markers."

  • 03

    Oct

  • 11

    Oct

KNSA Kiniksa
$26.47

1.62 (6.52%)

06/18/18
JMPS
06/18/18
INITIATION
Target $33
JMPS
Outperform
Kiniksa initiated with an Outperform at JMP Securities
Before the open, JMP Securities analyst Liisa Bayko started coverage of Kiniksa with an Outperform rating and $33 price target, stating that the company has put together a clinical-stage portfolio of three unique medicines that are "well spaced at different stages of development" in an "impressively short period of time."
06/18/18
WEDB
06/18/18
INITIATION
Target $31
WEDB
Outperform
Kiniksa initiated with an Outperform at Wedbush
Wedbush analyst David Nierengarten started Kiniksa with an Outperform rating and $31 price target as he believes shares are undervalued given the company's initial focus on late-stage, clinically de-risked assets for rare diseases with limited competition, as is the case for rilonacept in recurrent pericarditis and mavrilimumab in giant cell arteritis.
06/18/18
JPMS
06/18/18
INITIATION
Target $29
JPMS
Overweight
Kiniksa initiated with an Overweight at JPMorgan
JPMorgan analyst Anupam Rama started Kiniksa with an Overweight rating and $29 price target. The company has an emerging mid-stage auto-inflammation / auto-immune pipeline with multiple potential value creation catalysts over the next 6-24 months, Rama tells investors in a research note. He believes Kiniksa's pipeline is de-risked with "strong scientific rationale."
06/18/18
GSCO
06/18/18
INITIATION
Target $22
GSCO
Neutral
Kiniksa initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst Terence Flynn started Kiniksa Pharmaceuticals with a Neutral rating and $22 price target. The analyst is encouraged by the company's autoimmune focus and a number of near-term catalysts, but he views the current valuation as fair.

TODAY'S FREE FLY STORIES

MSM

MSC Industrial

$83.37

-0.44 (-0.52%)

04:55
04/20/19
04/20
04:55
04/20/19
04:55
Conference/Events
MSC Industrial management to meet with William Blair »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

  • 21

    Apr

  • 22

    Apr

  • 23

    Apr

  • 24

    Apr

  • 05

    Jun

  • 13

    Nov

KFS

Kingsway Financial

$2.30

-0.14 (-5.74%)

19:48
04/19/19
04/19
19:48
04/19/19
19:48
Hot Stocks
Kingsway Financial announces receipt of notification letter from NYSE »

Kingsway Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AWK

American Water

$104.63

2.32 (2.27%)

19:46
04/19/19
04/19
19:46
04/19/19
19:46
Hot Stocks
American Water signs contract to acquire East Pasadena Water Company »

California American…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 10

    May

FSNN

Fusion

$0.24

0.0048 (2.01%)

19:45
04/19/19
04/19
19:45
04/19/19
19:45
Hot Stocks
Fusion sees being delisted following receipt of Nasdaq delisting notice »

Fusion announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 30

    May

PSA

Public Storage

$217.43

0.81 (0.37%)

19:42
04/19/19
04/19
19:42
04/19/19
19:42
Hot Stocks
Public Storage announces change of Chief Legal Officer »

Public Storage announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 02

    May

  • 04

    Jun

V

Visa

$160.14

-0.33 (-0.21%)

19:40
04/19/19
04/19
19:40
04/19/19
19:40
Hot Stocks
Visa board elects Visa CEO Al Kelly as Chair »

Visa announced that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 09

    May

  • 29

    May

  • 05

    Jun

NAVB

Navidea

$0.17

0.0001 (0.06%)

19:39
04/19/19
04/19
19:39
04/19/19
19:39
Hot Stocks
Navidea announces one-for-twenty reverse stock split »

Navidea…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TISA

Top Image Systems

$0.84

-0.0069 (-0.81%)

19:37
04/19/19
04/19
19:37
04/19/19
19:37
Hot Stocks
Top Image sees voluntarily delisting to be complete before Nasdaq deadline »

Top Image Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCPT

Four Corners Property Trust

$28.17

0.49 (1.77%)

19:33
04/19/19
04/19
19:33
04/19/19
19:33
Hot Stocks
Four Corners Property Trust acquires restaurant properties for $2.6M »

Four Corners Property…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

PRK

Park National

$93.98

-2.72 (-2.81%)

19:32
04/19/19
04/19
19:32
04/19/19
19:32
Earnings
Park National reports Q1 EPS $1.62, two estimates $1.61 »

Commercial loans grew…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 29

    May

STNE

StoneCo

$26.50

-8.25 (-23.74%)

19:29
04/19/19
04/19
19:29
04/19/19
19:29
Hot Stocks
StoneCo says latest incentive offers from competitors don't change strategy »

StoneCo released a CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jun

GPIC

Gaming Partners

$13.09

(0.00%)

19:24
04/19/19
04/19
19:24
04/19/19
19:24
Hot Stocks
Gaming Partners sees acquisition by Angel closing on May 1 »

Gaming Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCHW

Charles Schwab

$45.57

-0.53 (-1.15%)

17:04
04/19/19
04/19
17:04
04/19/19
17:04
Conference/Events
Charles Schwab to hold a webcast »

Management holds a 2019…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 15

    May

12:45
04/19/19
04/19
12:45
04/19/19
12:45
General news
Breaking General news story  »

Week of 4/19 Baker-Hughes…

MMNFF

MedMen

$0.00

(0.00%)

11:13
04/19/19
04/19
11:13
04/19/19
11:13
Hot Stocks
MedMen announces resignations of COO and General Counsel »

MedMen Enterprises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TKC

Turkcell

$5.49

-0.175 (-3.09%)

11:08
04/19/19
04/19
11:08
04/19/19
11:08
Hot Stocks
Turkcell sees conclusion of $4.2B lawsuit against MTN this year »

The following statement…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCCY

1st Constitution Bancorp

$18.07

-0.14 (-0.77%)

11:05
04/19/19
04/19
11:05
04/19/19
11:05
Earnings
1st Constitution Bancorp reports Q1 EPS 39c, two estimates 36c »

Robert Mangano, President…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QUMU

Qumu

$2.83

-0.035 (-1.22%)

11:03
04/19/19
04/19
11:03
04/19/19
11:03
Hot Stocks
Qumu announces death of director Thomas Madison »

Qumu Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 09

    May

FAT

Fat Brands

$5.15

0.065 (1.28%)

10:54
04/19/19
04/19
10:54
04/19/19
10:54
Hot Stocks
Fat Brands announces development of Fatburger concept in Albuquerque »

FAT Brands announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HRTG

Heritage Insurance

$14.32

0.25 (1.78%)

10:52
04/19/19
04/19
10:52
04/19/19
10:52
Hot Stocks
Heritage Insurance announces preliminary Q1 catastrophe losses of $15.4M »

Heritage Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

COTY

Coty

$11.27

0.02 (0.18%)

10:48
04/19/19
04/19
10:48
04/19/19
10:48
Hot Stocks
Coty notes extension of tender offer by affiliate of JAB Holding Company »

Coty notes the extension…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTES

NetEase

$265.88

-2.34 (-0.87%)

10:45
04/19/19
04/19
10:45
04/19/19
10:45
Hot Stocks
NetEase announces music license agreement with Nippon Columbia »

NetEase Cloud Music…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:10
04/19/19
04/19
09:10
04/19/19
09:10
General news
Today's U.S. housing report revealed March declines »

Today's U.S. housing…

08:45
04/19/19
04/19
08:45
04/19/19
08:45
General news
U.S. housing starts fell 0.3% to 1.139 M in March »

U.S. housing starts fell…

08:15
04/19/19
04/19
08:15
04/19/19
08:15
General news
Housing Starts to be reported at 08:30 »

March Housing Starts will…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.